Figure 3.

Percentages of subjects with pain reductions of ≥30% and ≥50% from baseline to 24 hours, according to W2LOCF analysis (*P≤0.05 vs placebo).

Abbreviations: IV, intravenous; W2LOCF, 2-hour windowed last observation carried forward.